Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

BioRestorative Therapies Initiates Phase 2 Clinical Trial

To Treat Chronic Lumbar Disc Disease – Site Selection Underway

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has initiated the site selection process for its active Phase 2 clinical trial targeting chronic lumbar disc disease.

BioRestorative’s Phase 2 trial is a double-blind controlled, randomized study to evaluate the safety and preliminary efficacy of a single dose intradiscal injection of BRTX-100. A total of up to 99 eligible patients will be randomized at 15 centers in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.

“As we prepare to initiate enrollment for our Phase 2 clinical trial and first patient dosed, we will carefully vet our clinical sites so that each is capable of meeting our trial goals and timelines.” said Lance Alstodt, the Company’s CEO.

Mr. Alstodt continued, “Site selection is a critical process in clinical trials. PRC Clinical (the Company’s CRO) and BioRestorative are evaluating clinical sites with a proven track record in disc and pain related studies. The track record will include a comprehensive understanding of, and a careful adherence to, good clinical practice (GCP) trial guidelines. A well-trained, experienced clinic staff is also essential, as is a patient population that is capable of meeting study enrollment goals and timelines.”

“PRC Clinical has extensive experience in managing and executing clinical trials, especially as they relate to cell-based therapies to target pain related disorders. We are identifying qualified sites with a proven track record capable of meeting BioRestorative’s enrollment and trial timeline,” said Curtis Head, CEO of PRC Clinical.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine